Unverified50% confidenceOpinionExact time
AlphaFold lowered the barrier to early target assessment and structure-based drug design, but it provides structural hypotheses rather than biological validation; predicted structures still require experimental confirmation and cannot replace functional experiments and preclinical toxicology assessments.
1
Sources
50%
Confidence
Long-term
Relevance
10/15/2026
First Seen
Sources
Related Entities
Related Claims
UnverifiedThe authors position the contribution of this study as methodological robustness under fragmented assessment, rather than providing a clinical drug resistance ranking.66% similarUnverifiedThe researchers note that these findings establish the technical feasibility of LLM orchestration architecture in coordinating heterogeneous radiotherapy capabilities, but do not demonstrate clinical correctness, clinical utility, or prospective benefit.66% similarUnverifiedRegular expressions that pass initial benchmark testing may still expose problems under more rigorous adversarial probing, meaning passing a benchmark does not equate to true reliability.65% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/1035043API
curl https://kongchang.com/api/v1/knowledge/claims/1035043MCP
get_claim(id=1035043)